Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Scottsdale/Phoenix, Arizona: 12-004154
NCT ID: NCT01672164
Sponsor Protocol Number: CTOT-14
About this study
The main focus of this study is to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had a liver transplant. Researchers will examine blood, urine, and tissue samples and try to identify markers for certain conditions such as rejection, response to therapy, and scarring of the liver. Additionally, researchers would like to identify biomarkers that can detect damage to the native kidneys before blood levels of creatinine rises. By studying gene expression, researchers hope to be able to diagnose these conditions earlier and improve liver survival.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Subjects undergoing primary deceased-donor or living donor liver transplantation.
- Subject must be able to understand and provide informed consent.
Exclusion Criteria:
- Need for combined organ transplantation
- Previous solid organ and/or islet cell transplantation
- Infection with HIV
- Allergy to Iodine
- Inability or unwillingness of a participant to comply with study protocol
- Any condition that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Scottsdale/Phoenix, Ariz.
Mayo Clinic principal investigator Adyr Moss, M.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available